Daily Hot List: Salem Media Group, Inc., Huntington Ingalls Industries (NYSE:HII), ACADIA Pharmaceuticals (NASDAQ:ACAD), Conatus Pharmaceuticals (NASDAQ:CNAT)

Regions Financial Corporation (NYSE:RF) shares advanced 1.02% in last trading session and ended the day at $7.90. RF has a return on assets of 0.70%. Regions Financial Corporation (NYSE:RF) quarterly performance is -16.67%.

Salem Media Group, Inc. (NASDAQ:SALM) ended the last trading day at $3.90. Company weekly volatility is calculated as 3.17% and price to cash ratio as 496.28. Salem Media Group, Inc. (NASDAQ:SALM) showed a weekly performance of 4.00%.

Zacks Investment Research upgraded shares of Salem Media Group Inc (NASDAQ:SALM) from a hold rating to a buy rating in a report released on Monday, MarketBeat reports. Zacks Investment Research currently has $4.25 price target on the stock.

On 04 February, Huntington Ingalls Industries, Inc. (NYSE:HII) shares advanced 0.25% and was closed at $125.95. HII EPS growth in last 5 year was 22.00%. Huntington Ingalls Industries, Inc. (NYSE:HII) year to date (YTD) performance is -0.71%.

Huntington Ingalls Industries (NYSE:HII) will release its fourth quarter 2015 financial results on Thursday, Feb. 18 and host an earnings conference call at 9 a.m. EST the same day.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares advanced 7.41% in last trading session and ended the day at $20.29. ACAD has a return on assets of -51.20%. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) quarterly performance is -52.01%.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), announced that it will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016, at 8:00 a.m. Eastern Time in New York City.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) caters to the Healthcare space. Its weekly performance is 15.63%. On the last day of trading company shares ended up at $1.85.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s emricasan development program for the treatment of liver cirrhosis caused by nonalcoholic steatohepatitis (NASH). Based on additional communications with the FDA recommending single-etiology clinical trials, the company plans to focus on advancing toward initial registration of emricasan for patients with NASH cirrhosis, with parallel development toward registration of emricasan for patients with NASH fibrosis, and supportive clinical trials addressing additional patient populations.